Targeting QPCTL: An Emerging Therapeutic Opportunity.

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Glutaminyl cyclases, including QPCT and QPCTL, convert N-terminal glutamine/glutamate to pyroglutamate.
• QPCTL modifies CD47, impacting immune cell phagocytosis of tumor cells.
• QPCTL also affects chemokines CCL2, CCL7, and CX3CL1, influencing cancer and inflammation.

Purpose of the Study:

• To review the structural features, catalytic mechanisms, and biological functions of QPCTL.
• To summarize recent advances in small-molecule QPCTL inhibitors.
• To provide insights for developing novel QPCTL inhibitors.

Main Methods:

• Literature review of structural, mechanistic, and functional studies on QPCTL.
• Analysis of recent developments in small-molecule inhibitor research for QPCTL.

Main Results:

• QPCTL's role in CD47-SIRPα pathway and chemokine modulation is highlighted.
• Early-stage development of QPCTL inhibitors is noted.
• QPCTL's therapeutic potential in various diseases is established.

Conclusions:

• QPCTL is a promising therapeutic target for cancer and inflammatory disorders.
• Further research into QPCTL inhibitors is crucial for therapeutic development.
• Understanding QPCTL's structure and function is key to designing effective inhibitors.